A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Abroad (travel likely)RecruitingPHASE3

Conditions

Hemophilia A

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Nara Medical University Hospital, Kashihara-shi, Nara, Japan
Tokyo Medical University Hospital, Shinjuku-Ku, Tokyo, Japan

Study leads

Clinical Trials
Study Director
Hoffmann-La Roche

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Abroad (travel likely)RecruitingPHASE1, PHASE2

Sacramento, United States · Washington D.C., United States

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Hemophilia

Abroad (travel likely)RecruitingPHASE3

Los Angeles, United States · Orange, United States

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

Severe Hemophilia A

Abroad (travel likely)RecruitingPHASE3

Tianjin, China · Fuyang, China

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Hemophilia A

Abroad (travel likely)RecruitingPHASE3

Atlanta, United States · Atlanta, United States